Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Avenue Therapeutics, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 7 | 0 | −7 |
| Shares | 192.6K | 0 | −192.6K (−100.0%) |
| Value | $385.3K | $0 | −$385.3K (−100.0%) |
New holders (0)
Institutions that held Avenue Therapeutics, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
None.
Sold out (7)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Ikarian Capital, LLC | 140,000 | $280.0K |
| Boothbay Fund Management, LLC | 41,089 | $82.2K |
| UBS Group AG | 7,920 | $15.8K |
| Tower Research Capital LLC (TRC) | 3,096 | $6.19K |
| Wells Fargo & Company | 500 | $1.00K |
| Bank of America Corp | 14 | $28 |
| SBI Securities Co., Ltd. | 9 | $18 |